Introduction
Carbapenem-resistant gram-negative bacteria (CR-GNB), including carbapenem-resistant
Klebsiella pneumoniae (CRKP), -
Acinetobacter baumannii (CRAB), and -
Pseudomonas aeruginosa (CRPA), and so on, have emerged as a glaring global public health crisis with very few effective treatment regimens and are associated with a high mortality [
1,
2]. Abdominal solid organ transplantation (ASOT) has already been identified as a risk factor for CR-GNB infections. To date, several previous studies have investigated the worldwide spread of carbapenem-resistant
Enterobacteriaceae (CRE) infections among ASOT recipients, showing mortality rates up to 71% [
3]. It is a great challenge to make antimicrobial decisions in these patients because CR-GNBs are mostly extensively drug resistant (XDR) and only susceptible to a few antibiotics. CRKP bloodstream infections led to a mortality rate as high as 82% after liver transplantation [
4], and the mortality associated with CRAB infections among kidney recipients was also up to 56% [
5].
Comparative drug studies focused on CR-GNB infections in ASOT recipients are limited, and most failed to differentiate between transplant and nontransplant patients. Although some studies have been carried out on CRE or CRAB infections, few have investigated the epidemiology, drug resistance, and clinical outcomes of ASOT recipients with CR-GNB infections in China [
6,
7].
This study therefore set out to characterize the epidemiology, microbiology, and risk factors related to 90-day mortality among ASOT recipients with CR-GNB infections. Thus, our findings may shed light on the improvement of clinical outcomes and the antimicrobial regimen for CR-GNB infections among this special patient population.
Methods
Design
All the electrical medical records of 1452 ASOT recipients from August 1, 2013, to August 1, 2020, were retrospectively reviewed. As Fig. S1 shows, a two-part analysis was performed (1) to evaluate the risk factors associated with 90-day mortality and (2) to identify the drug resistance of CR-GNB pathogens.
Setting
The retrospective cohort study was performed at the Third Xiangya Hospital of Central South University, an 1800-bed tertiary-care teaching hospital with a long-term ASOT program (annual average of 180 kidney and 35 liver transplantations), Changsha, China.
Patients
Patients < 16 or > 80 years old were excluded. There were only two sources of organs harvested for transplantation: living-related donors and donors after citizen’s death. The prophylactic regimen used 1 h before transplantation was beta-lactamase inhibitors/semisynthetic penicillin, second- or third-generation cephalosporins, or carbapenems. According to the result of the culture before transplantation, a precise antibiotic was given within 72 h after transplantation. The treatment we recorded was the initial regimen after obtaining the microbiology profile. Tigecycline was used at 50 mg every 12 h (100 mg the first time) and mostly in the abdominal cavity or deep wounds and skin infections instead of bloodstream infections as monotherapy. High-dose (2 g every 8 h), extended-infusion meropenem (over 3 h) was considered an appropriate therapy for initial treatment. Due to limited drug resistance tests of polymyxin and ceftazidime-avibactam, prescriptions of both antibiotics as effective options depended on the patient's condition. Data on the subsequent microbiology profile and corresponding treatment were not collected. For patients experiencing more than one episode of CR-GNB infection, only the first episode was included.
Definition and Microbiology
The onset of CR-GNB infections referred to the collection date of the first positive culture with clinical evidence of infections. Patients with positive microbiology results, according to the criteria of the Centers for Disease Control, were defined as having infections [
8]. Donor-derived infections were defined as the same infections that were transmitted from the donor to more than one recipient [
9].
Appropriate empirical antimicrobial therapy indicated that antibiotics susceptible to CR-GNB in vitro were prescribed to treat suspected CR-GNB infections within 48 h after having drawn the cultures of specimens. Treatment during the initial stage of infections was categorized as monotherapy or combination therapy. Combination therapy was defined as treatment with two or more agents active in vitro against the infecting strain. Septic shock was diagnosed in recipients with CR-GNB infections who required vasopressor therapy to maintain mean arterial pressure of at least 65 mmHg with serum lactate level > 2 mmol/l after adequate fluid resuscitation [
10]. Crude mortality included all causes of death within 90 days after the onset of infections.
Identification and antimicrobial susceptibility testing of CR-GNB were carried out using the Vitek-2 system (bioMérieux, Marcy L’etoile, France). Antimicrobial susceptibility was determined by the Kerby-Bauer disk diffusion method, and the minimum inhibitory concentration was measured by agar dilution in the National Committee for Clinical Laboratory Standards guidelines. All the antimicrobial agents were products of Oxoid Ltd., Hampshire, UK. Intermediate susceptibility to the antibiotics was considered as resistance. The strain was considered to be CR-GNB when the minimal inhibitory concentration of meropenem or imipenem was ≥ 2 mg/l [
11].
Data Collection and Variables
The clinical and demographic characteristics included: age, sex, hallmarks of infections (temperature and white blood cell count), site of infection, re-operation, mechanical ventilation, hospital-acquired infections, septic shock, empirical antimicrobial therapy, type of transplantation, and treatment regimen. Laboratory records, collected within the first 24 h after the culture was drawn, included: the serum albumin level, total bilirubin and creatinine levels, and platelet and lymphocyte counts.
Outcomes
The follow-up period for all the patients was 3 months (90 days) after the onset of infections. The patients with < 3 months of follow-up were excluded from the cohort. The clinical outcomes were divided into death and alive for risk analysis.
Ethics
The Institutional Review Board of the Third Xiangya Hospital of Central South University endorsed this study protocol prior to data collection (number: 2020-S629). The Institutional Review Board approved the waiver of informed consent from patients because this was a retrospective cohort study where information was obtained from electrical medical records and this study did not directly interfere with the enrolled patients as the data were de-identified and anonymously analyzed. Our study was conducted according to the Declaration of Helsinki and the Declaration of Istanbul, and no donors influenced or paid for our study. As a privacy statement, the authors guarantee the confidentiality of the patient data.
Statistical Analysis
For continuous variables, data were expressed as median (25–75% quartile) or mean (± SD). Categorical variables were compared with the χ2 test or Fisher exact tests. Univariate analysis was applied to inspect the association between variables and mortality caused by CR-GNB infections. The follow-up time was analyzed and defined as days alive from the onset until day 90, and a Cox regression (forward likelihood ratio method) analysis was performed to model hazards using this time variable. Hazard ratio (HR) and 95% confidence intervals (CI) were calculated to assess the strength of all relations. The Kaplan-Meier curve was used to describe the survival distribution, and the log rank test was used to compare survival time among all the independent risk factors. Statistical significance was defined as P < 0.05 (two-tailed), and all analyses were carried out using SPSS 24.0 (IBM SPSS Statistics, IBM Corp., Armonk, NY, US).
Discussion
CR-GNBs have spread worldwide with limited choice of antibiotic therapy in recent years. ASOT recipients were vulnerable with all the definite risk factors related to CR-GNB infections, such as recurrent exposure to prophylactic antibiotics, intensive care unit, massive healthcare contact, and longer length of hospitalization. Rising mortality rates caused by CR-GNB infections have been reported in a variety of susceptible populations, including ASOT recipients [
3,
12]. This is the largest cohort study to characterize the epidemiology, risk factors, microbiologic spectrum, and clinical outcomes associated with CR-GNB infections among ASOT recipients in China to date.
In our present study, we revealed a morbidity and mortality rate of CR-GNB infections among ASOT recipients of up to 10.5% and 23%, respectively. The prevalence of CR-GNB was higher in liver recipients (18.8%) than in kidney recipients (8.7%). The possible reasons may be the longer operation duration, more transfusions during surgery, and longer postoperative intensive care unit stay. To date and to our knowledge, this current analysis includes more deaths due to CR-GNB infections than previous studies, which only focused on one category of CR-GNB such as CRKP or CRAB [
4,
13].
Mechanical ventilation, septic shock, and platelet count < 50,000/mm
3 were found to be three independent risk factors associated with 90-day mortality. Septic shock was the most severe complication of infections in ASOT recipients with limited clinical approaches. The relationships among mortality, mechanical ventilation, and septic shock concluded from our present study were similar to those found in previous studies [
7,
14‐
17]. This is not surprising because requiring mechanical ventilation and septic shock are indicators of the severity of illness. This finding underscores the importance of early therapy, including timely and adequate antibiotic therapy, which may increase the survival rate of ASOT recipients suffering from septic shock or respiratory failure [
18]. In line with our previous study, platelet count < 50,000/mm
3 predicted adverse clinical outcomes of CR-GNB-infected recipients [
19]. It probably resulted from the key role of the platelets in the development of disseminated intravascular coagulation and multiple organ failure despite the unclear mechanisms [
20].
Donor-derived infections, especially CR-GNB infections, were increasingly reported with adverse impacts on the recipient outcomes in the past decades [
21‐
23]. In line with previous study, we found that donor-derived infections were not related to mortality with a
P value of 0.997, indicating CR-GNB-infected or -colonized donors could also be transplanted with prophylactic antibiotic therapy in the current era of donor shortages [
23].
Choosing appropriate antibiotics for CR-GNB infections is a great challenge due to the complex clinical situation. The overall drug resistance rates of pathogens to various categories of antibiotics, antibiotic concentration, tissue penetration at the site of infections, and renal and liver function for ASOT recipients must be considered.
TGC is a broad-spectrum antibiotic with in vitro activity against CR-GNB and approved as an appropriate therapy except for CRPA. Approximately 33.3% of CR-GNB pathogens in the present study were resistant to TGC, in line with the previous study reporting the drug resistance rate of 37.8% among inpatients [
24]. After eliminating the impact of CRPA (
n = 9) on the total drug resistance rate, there were only 27.5% other CR-GNBs resistant to TGC, making it an appropriate ‘old’ antibiotic for the treatment of CR-GNB infections among ASOT recipients. In line with previous studies, combination therapy, based on TGC, was recommended as the most effective regimen used for CR-GNB infections, particularly for CRE infections in China [
25]. TGC performs poorly in bacteremia because of the poor plasma concentration [
26]. We did not monitor plasma or tissue concentrations of TGC because of the retrospective nature. Guner et al. revealed that TGC, used alone or in combination with other antibiotics, was effective in CRAB infections [
27]. However, there was a significantly increasing trend in the drug resistance rate of TGC (from 24 to 40%,
P = 0.04) as time went on, which may be an alert for cautious prescription of TGC.
We also revealed that drug resistance rates of all CR-GNB isolates to nine of ten antibiotics involved were > 60% except for TGC. CRAB (
n = 47) and CRKP (
n = 39) were the most common pathogens in this cohort. Consistent with the previous studies, CRKP and CRAB were both highly resistant (> 50%) to the other nine of ten antibiotics except for TGC [
28,
29]. For carbapenem-resistant
E. coli and other CR-GNB organisms, drug resistance rates were basically lower than for CRKP and CRAB. These other nine antibiotics were not recommended as empirical therapy for CR-GNB infections because of the high probability of failure based on our findings. Several previous studies proved that some of these antibiotics, such as trimethoprim-sulfamethoxazole and amikacin, performed well in CRKP infections among ASOT recipients, so we suggest that these choices may be prescribed after identification of susceptibility [
30,
31]. The new rapid diagnostic options for CR-GNB, such as next-generation sequencing and ATP bioluminescence, are recommended in treatment to improve outcomes, but are limited because of the exorbitant costs [
32].
Polymyxins, both colistin and polymyxin B, were successful and safe choices for ASOT recipients reported in previous studies but not analyzed in this cohort because of the lack of susceptibility profiles in most patients [
33,
34]. Cefiderocol, a novel cephalosporin designed to treat all CR-GNB infections, is still in the clinical trial stage with promising prospects [
35]. Ceftazidime avibactam has been reported to have better effects than TGC, thus being approved to treat CR-GNB infections in China since May 21, 2019 [
36,
37]. However, administering combination or ‘new’ antibiotic therapy to all severe CR-GNB infected patients, including some individuals with XDR or pan-drug-resistant pathogens, is not a sustainable decision due to the concerns about deteriorating resistances. In the present era of emerging drug resistance, prospective steps may be suggested to facilitate pharmacologic and molecular studies to speed up the process of creating clinical breakpoints for novel antibiotics, including all new antibiotics mentioned above, and define the mechanism of drug resistance.
Certain limitations need to be clarified in our study. First, due to the retrospective nature of a monocentric study, our research is limited by deficient data retrieved from the electronic medical records. The impact of antibiotics, comparing ‘new’ with ‘old,’ may hardly be evaluated in our cohort and needs to be investigated in a prospective study. Second, our study could be divided into various groups, such as different age groups, to provide more detailed information, which may be done in the future. Third, the immune status of ASOT recipients may play an important role, as all patients were immunosuppressed; therefore, we will reveal the relationship related to the rate of CD4/CD8 or IgG/IgA/IgM levels and clinical outcomes in the future. Finally, with the development of medical technology, it might be possible to use novel molecular technology or test methods to investigate the mechanism and allow prompt rapid diagnoses of infections.
Acknowledgements
We thank Profs. Tubao Yang and Junxia Yan for their help in verifying the statistical analysis in this manuscript.